[go: up one dir, main page]

IN2012DN02423A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02423A
IN2012DN02423A IN2423DEN2012A IN2012DN02423A IN 2012DN02423 A IN2012DN02423 A IN 2012DN02423A IN 2423DEN2012 A IN2423DEN2012 A IN 2423DEN2012A IN 2012DN02423 A IN2012DN02423 A IN 2012DN02423A
Authority
IN
India
Prior art keywords
mif
cxcr2
cxcr4
homomultimer
inhibits
Prior art date
Application number
Inventor
Jurgen Bernhagen
Christian Weber
Benedikt Vollrath
Court Turner
Joshua Robert Schultz
Alma Zernecke
Sergio Duron
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Publication of IN2012DN02423A publication Critical patent/IN2012DN02423A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein, in some embodiments, are methods for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an agent that inhibits (i) MIF binding to CXCR2 and CXCR4 and/or (ii) MIF- activation of CXCR2 and CXCR4; (iii) the ability of MIF to form a homomultimer; or a combination thereof.
IN2423DEN2012 2009-09-23 2010-09-23 IN2012DN02423A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24521409P 2009-09-23 2009-09-23
US31903910P 2010-03-30 2010-03-30
PCT/US2010/050047 WO2011038149A2 (en) 2009-09-23 2010-09-23 Methods of treating inflammation

Publications (1)

Publication Number Publication Date
IN2012DN02423A true IN2012DN02423A (en) 2015-08-21

Family

ID=43796491

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2423DEN2012 IN2012DN02423A (en) 2009-09-23 2010-09-23

Country Status (9)

Country Link
EP (1) EP2480579A4 (en)
KR (1) KR20120105429A (en)
CN (1) CN102725311A (en)
AU (1) AU2010298249A1 (en)
BR (1) BR112012006468A2 (en)
CA (1) CA2773978A1 (en)
IN (1) IN2012DN02423A (en)
MX (1) MX2012003514A (en)
WO (1) WO2011038149A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9328174B2 (en) * 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
NZ702315A (en) * 2012-05-17 2016-10-28 Cyon Therapeutics Inc Methods and uses for pro protein convertase subtilisin kexin 9 (pcsk9) inhibitors
WO2015071416A2 (en) * 2013-11-14 2015-05-21 Baxter Healthcare Sa Mif as therapeutic target
CA3017345A1 (en) 2016-03-11 2017-09-14 Ardea Biosciences, Inc. Cxcr-2 inhibitors for treating crystal arthropathy disorders
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
AU2019417313B2 (en) * 2018-12-26 2023-01-19 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
US20230104343A1 (en) * 2020-03-11 2023-04-06 Biolinerx Ltd. Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
WO2021219495A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN112656934A (en) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 Application of polypeptide AT03 in medicine for treating primary biliary cholangitis
EP4378319A1 (en) * 2022-12-01 2024-06-05 Bioiberica, S.A.U. Composition comprising bioactive peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
AU2003213647A1 (en) * 2002-02-27 2003-09-09 Emory University Multimeric binding complexes
AU2003215732B2 (en) * 2002-03-01 2009-12-17 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US7897349B2 (en) * 2003-12-30 2011-03-01 The United States Of America As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (MIF) as marker for urological inflammatory disease
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN102088993A (en) * 2008-03-20 2011-06-08 卡罗勒斯治疗公司 Methods of treating inflammation
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Also Published As

Publication number Publication date
AU2010298249A1 (en) 2012-04-19
WO2011038149A2 (en) 2011-03-31
WO2011038149A3 (en) 2011-10-27
BR112012006468A2 (en) 2016-08-09
KR20120105429A (en) 2012-09-25
CN102725311A (en) 2012-10-10
MX2012003514A (en) 2012-04-19
EP2480579A2 (en) 2012-08-01
CA2773978A1 (en) 2011-03-31
EP2480579A4 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
IN2012DN02423A (en)
WO2009117710A3 (en) Methods of treating inflammation
MX2010006823A (en) Methods for the treatment of gout.
TW200738262A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
MX2010009724A (en) Methods of treating inflammatory pain.
MY191313A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
EP3489360A3 (en) Modulation of nuclear-retained rna
MX2011007930A (en) Crystalline insulin-conjugates.
WO2010005524A3 (en) Abdominal aortic aneurysms: systems and methods of use
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2010003013A (en) Inhibition of angiogenesis.
MX2011006725A (en) Combination of aurora kinase inhibitors and anti-cd20 antibodies.
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2009016488A3 (en) Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
SG179069A1 (en) Cancer stem cell-targeted and drug resistant cancer therapy
WO2011041325A3 (en) Methods and compositions for the treatment of viral disorders
MX2011012538A (en) Combination therapy for the treatment of multiple myeloma.
EP2566502A4 (en) Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
AU2010298020A8 (en) Combination
WO2008073317A3 (en) Cytarabine for treatment of glioma
TN2011000206A1 (en) Compositions and methods of use soluble thrombomodulin variants
PH12012500873A1 (en) Multilayer pharmaceutical composition that can be dispersed in water and which contains a combination of antimalarial agents
UA41936U (en) Method for treating kraurosis of vulva in children
UA29207U (en) Method for miscarriage treatment